Clinical Trials Sponsored by UNC Lineberger Comprehensive Cancer Center

Total 5620 results

UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Liver Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer

Esophageal Cancer
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy

Lung Cancer
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb

Terminated

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Sivan Innovation Ltd.

Completed

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare® (LC-PRO)

Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung

United States
UNC Lineberger Comprehensive Cancer Center
Lantheus Medical Imaging

Completed

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau (CEUS-VHL)

Kidney Disease, Chronic | Von-Hippel Lindau

United States
UNC Lineberger Comprehensive Cancer Center
Pfizer; BioMed Valley Discoveries, Inc

Recruiting

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Melanoma | Pancreatic Cancer | Tumor, Solid

United States
UNC Lineberger Comprehensive Cancer Center
Astellas Pharma Global Development, Inc.

Completed

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Non Small Cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Olaparib in LA-HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Recruiting

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Cancer | Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center
Hyundai Hope On Wheels

Recruiting

UNC Childhood, Adolescent, and Young Adult Cancer Cohort (UNC-CAYACC)

Cancer | Pediatric Cancer | Survivorship | Cancer Metastatic

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Bladder Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

Head and Neck Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Terminated

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

Endometrial Cancer | Uterine Cancer

United States
Hospital San Carlos, Madrid
UNC Lineberger Comprehensive Cancer Center

Completed

Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer

Breast Cancer

Spain
UNC Lineberger Comprehensive Cancer Center
Patient-Centered Outcomes Research Institute

Completed

North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate

United States
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Recruiting

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Multiple Myeloma | Aging | Relapse | Co-morbidity | Refractory

United States
UNC Lineberger Comprehensive Cancer Center
Doris Duke Charitable Foundation

Recruiting

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology (PRO-VISION)

Renal Cell Carcinoma

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Acute Myeloid Leukemia, in Relapse

United States
UNC Lineberger Comprehensive Cancer Center
The Thoracic Surgery Foundation

Completed

Improving Quality of Life After Thoracic Surgery Using Patient-Reported Outcomes

Thoracic Surgery

United States
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; Amgen

Active, not recruiting

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Colon Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
LCCC Geriatric Oncology Program

Completed

Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer

Fatigue | Colorectal Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Genzyme, a Sanofi Company

Completed

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Withdrawn

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

Non Small Cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Radiation Therapy Oncology Group

Completed

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Completed

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
United States Department of Defense; Bellicum Pharmaceuticals; University Cancer...

Recruiting

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Osteosarcoma | Neuroblastoma

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Syndax Pharmaceuticals

Terminated

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Breast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
UNC Translational and Clinical Sciences (Tracs)

Completed

Retinal Oxygen Function After Radiation Therapy

A History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health (NIH)

Recruiting

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Epithelial Ovarian Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Radiological Society of North America

Suspended

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Endometrial Cancer | Complex Atypical Hyperplasia

United States
UNC Lineberger Comprehensive Cancer Center
American Society of Clinical Oncology

Recruiting

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences

Completed

mHealth Physical Activity Intervention for Survivors of Adolescent and Young Adult Cancers (THRIVE)

Cancer | Physical Activity

United States
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences

Completed

Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Androgen Deprivation Therapy

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); East Carolina University

Active, not recruiting

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE) (SCORE)

Colorectal Cancer

United States
UNC Lineberger Comprehensive Cancer Center
American Society of Clinical Oncology

Recruiting

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Head and Neck Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
The V Foundation; Bellicum Pharmaceuticals

Recruiting

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Immune System Diseases | Lymphoma | Lymphoma, B-Cell | Lymphatic Diseases | Immunoproliferative Disorders

United States
UNC Lineberger Comprehensive Cancer Center
National Institute on Aging (NIA)

Terminated

Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM) (PaCE-MM)

Multiple Myeloma

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Otsuka America Pharmaceutical

Completed

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (LCCC0510)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
Doris Duke Charitable Foundation; Conquer Cancer Foundation

Active, not recruiting

Metastatic Breast Cancer-Specific Prognostic Tool

Metastatic Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Syndax Pharmaceuticals

Active, not recruiting

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Bladder Cancer

United States

Clinical Trials Sponsored by UNC Lineberger Comprehensive Cancer Center

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations